ArticleCureus2024
Trends in the Incidence of Brain Cancer: An Observational Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Fluorescent-Based Analysis of T Cells and T-Cell-Dependent Bispecific Antibody in a Brain Tumor Mouse Model.Methods in molecular biology (Clifton, N.J.) · 2026Article
- MEX3A is a diagnostic, independent prognostic biomarker and a promising therapeutic target in glioblastoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain cancer is a serious global health problem, leading to increasing mortality and morbidity. Understanding the risk factors is crucial in early diagnosis and treatment. This retrospective cohort study thus aimed at assessing the temporal trends in the incidence of brain cancer based on age, gender, and race from 1999-2020.
methodsThe brain cancer incidence based on age, gender, and race were retrieved from the CDC WONDER database on May 18, 2024. Data were collected individually for each year (from 1999 to 2020), as well as for age (from <15 years to ≥ 75 years with a 10-year range in each group), gender, race, and all states, covering the overall incidence from 1999 to 2020. Additionally, data was aggregated for combined years and age, combined years and sex, and combined years and race. Statistical analysis was done via Rv4.3.2 and included the calculation of crude rates and representation of data via bar graphs and line diagrams.
resultsOur study revealed that out of a total population of 6,722,531,044 analyzed, the crude rate per 100,000 was 6.6 over 20 years. The incidence was highest in the 65-74 year age range (19.76%), among males (55.85%), and the white race (88.96%). The temporal trends overall show a rising trend in the crude rate of brain cancer, with the highest incidence in 2019, followed by a steep decline thereafter.
conclusionsOur study found that the crude rate of brain cancer from 1999-2020 was 6.6 per 100,000, with the highest incidence in the 65-74 age group, among males, and within the white population. The overall trend showed an increase in brain cancer incidence, peaking in 2019, particularly among younger age groups, with stable or declining rates in older adults and non-white races.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.